First-pass extracted concept

AAV-based gene therapy for hemophilia

Candidate: concept label1 source documents3 linked claims

Jump to evidence Jump to sources Jump to claims

Live refresh every 5sNext refresh in 5s

Aliases

AAV gene therapy, hemophilia gene therapy

Evidence Snippets

Adeno-associated virus (AAV)-based gene therapy offers the potential for long-term functional cure in patients with hemophilia A and B.

Evidence 1Source 1DOI PubMedprovenance

Supporting Sources

Source 1primary paper2026MEDDOI PubMed

1 evidence snippet 3 linked claims Claim 1 Claim 2 Claim 3

Linked Claims

Claim 1future directionsupports2026Source 1DOI PubMed

Future directions discussed for safer hemophilia AAV gene therapy include vector engineering, immune modulation, and personalized treatment approaches.

Quoted textsource-backed

provides an outlook on future directions including vector engineering, immune modulation, and personalized treatment approaches

Claim 2potential benefitsupports2026Source 1DOI PubMed

AAV-based gene therapy offers the potential for long-term functional cure in hemophilia A and B.

Quoted textsource-backed

Adeno-associated virus (AAV)-based gene therapy offers the potential for long-term functional cure in patients with hemophilia A and B.

Claim 3safety challengesupports2026Source 1DOI PubMed

Immune responses triggered by the AAV vector capsid or transgene product can lead to hepatotoxicity and are a major challenge to long-term transgene expression stability and treatment safety in hemophilia gene therapy.

Quoted textsource-backed

However, immune responses triggered by the vector capsid or transgene product, leading to hepatotoxicity, represent a major challenge to the long-term stability of transgene expression and treatment safety.